Deal roundup: Zymeworks/Celgene, Curis/Aurigene, MedImmune/NCI
Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.
Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.